Cargando…
Clinical Features and Treatment Progress of Invasive Mucormycosis in Patients with Hematological Malignancies
The incidence rate of invasive mucormycosis (IM) in patients with hematological malignancies (HMs) is increasing year by year, ranging from 0.07% to 4.29%, and the mortality rate is mostly higher than 50%. With the ongoing pandemic of COVID-19, COVID-19-associated mucormycosis (CAM) also became a gl...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219352/ https://www.ncbi.nlm.nih.gov/pubmed/37233303 http://dx.doi.org/10.3390/jof9050592 |